HPV DNA Tissue Testing
| Label Mnemonic: | HPVFFPE |
| Epic code: | LAB8863 |
| Downtime form: | A-1a Doctor/Provider Orders - Pathology Core and Specialty Care Nursery |
Commercial Mailout Laboratory
6240-8 RCP
356-8593
6240-8 RCP
356-8593
Specimen(s):
FFPE Solid Tumor Tissue
Specimen
Instructions:
Must have a copy of the surgical pathology report to send with slides.
Collection Medium:
) |
| Tissue Block |
Minimum:
Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides with tissue area approximately 100 mm2 cut at thickness of 5-10 microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
Delivery Instructions:
Use cold pack for transport, making sure cold pack is not in direct contact with specimen.
Turn Around
Time:
5-7 days upon receipt at reference laboratory
Comments:
This testing is not performed at the University of Iowa Hospitals and Clinics
HPV DNA Tissue Testing is preformed on FFPE tissue. It uses PCR and fragment analysis for qualitative detection and genotyping of human papillomavirus (HPV) low risk types 6/11 and high risk types 16, 18, 31, 33, 45, and 58. When detected, specific genotypes are identified except for 6 and 11 which cannot be distinguished from each other and are reported as positive for the combination 6/11.
Clinical Significance:
HPV DNA testing on FFPE tissue in head and neck squamous cell carcinomas (HNSCC), anogenital, and cervical lesions provides a complementary or alternative method to testing by p16 IHC or HPV ISH. In anogenital specimens, testing can distinguish presence of low-risk HPV types 6 and 11, associated with benign warts, from high-risk types which are associated with approximately 90% of anal cancers, 40% of vaginal cancers, and 40% of penile cancers. HPV is detected in up to 60-70% of oropharyngeal cancers and approximately 30% of HNSCC overall. HPV status serves as a prognostic marker head and neck cancer. Patients with HPV-positive cases have improved response to treatment and longer survival than patients with HPV-negative tumors in clinical trials.
HPV DNA Tissue Testing is preformed on FFPE tissue. It uses PCR and fragment analysis for qualitative detection and genotyping of human papillomavirus (HPV) low risk types 6/11 and high risk types 16, 18, 31, 33, 45, and 58. When detected, specific genotypes are identified except for 6 and 11 which cannot be distinguished from each other and are reported as positive for the combination 6/11.
Clinical Significance:
HPV DNA testing on FFPE tissue in head and neck squamous cell carcinomas (HNSCC), anogenital, and cervical lesions provides a complementary or alternative method to testing by p16 IHC or HPV ISH. In anogenital specimens, testing can distinguish presence of low-risk HPV types 6 and 11, associated with benign warts, from high-risk types which are associated with approximately 90% of anal cancers, 40% of vaginal cancers, and 40% of penile cancers. HPV is detected in up to 60-70% of oropharyngeal cancers and approximately 30% of HNSCC overall. HPV status serves as a prognostic marker head and neck cancer. Patients with HPV-positive cases have improved response to treatment and longer survival than patients with HPV-negative tumors in clinical trials.
Methodology:
Molecular
CPT Code:
87624